Loading organizations...
Key people at OXOLIFE.
OXOLIFE is a biotechnology company developing OXO-001, a first-in-class oral drug designed to enhance female fertility. This non-hormonal treatment specifically targets the endometrium to improve embryo implantation, addressing a critical factor in reproductive success. The company focuses on the development of novel therapies in reproductive health, applying a specialized approach to improve outcomes where current solutions are limited.
The company was established in 2013 in Barcelona by Agnès Arbat and Ignasi Canals. Dr. Arbat, a medical doctor specializing in clinical pharmacology, and Mr. Canals conceived the company from an understanding of the unmet medical need in reproductive health, particularly in supporting successful embryo implantation. Their combined expertise drives the scientific and clinical development of their lead product.
OXOLIFE primarily serves women undergoing assisted reproductive treatments, aiming to increase their chances of successful pregnancy. The company’s overarching vision is to significantly advance reproductive medicine by providing effective solutions that improve the embryo implantation process and enhance overall female fertility, ultimately striving to improve outcomes for individuals facing infertility challenges globally.
Key people at OXOLIFE.
Oxolife is a clinical-stage Barcelona-based biotech developing a first-in-class oral drug, OXO‑001, that aims to *enhance embryo implantation* and treat infertility including infertility associated with polycystic ovary syndrome (PCOS)[4][5]. Founded in 2013 by biochemist Ignasi Canals and clinical pharmacologist Agnès Arbat, the company has completed preclinical work and a Phase I safety study and raised equity to fund a Phase II program across European IVF centers[4][2].
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
Quick take: Oxolife is a focused clinical‑stage biotech addressing a large unmet need in reproductive medicine with a novel, patent‑protected oral candidate and growing institutional backing; the company’s trajectory now hinges on Phase II results that will determine whether its scientific promise translates into clinical and commercial reality[5][2].